Yesterday's announcement that Erbitux and chemotherapy proved effective in boosting survival in a late-stage trial for head and neck cancer could lead to a big boost in income for ImClone and Bristol-Myers Squibb. One analyst pegged the value of an additional approval as a first-line therapy for head and neck cancer at $350 million in annual sales. One of the keys to a successful added indication, though, will come when Erbitux is compared to a combination of chemotherapy and radiation, which is the standard therapy today.
- read the report on Erbitux from The Boston Globe
Related Articles:
Erbitux approved for head and neck cancers. Report
Analysts raise doubts on Erbitux ruling. Report
ImClone touts survival rate in Erbitux cancer trial. Report